Skip to content

West China Moonshot Project for Accelerating Prevention, Early Detection, Treatment and Prognosis of Lung Cancer

West China Lifelong Care & Collaborative Management Program for Lung Nodule & Lung Cancer Study - LCCM Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200056422
Enrollment
Unknown
Registered
2022-02-05
Start date
2019-03-14
Completion date
Unknown
Last updated
2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

Healthy control:To have Low-dose CT scans for regular physical examination
Lung nodule:To have low-dose CT scans following clinical routines
Lung cancer:To follow clinical routines on treatment and follow-ups

Sponsors

Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: The cohort is composed of three sub-cohorts including sub-cohort of healthy controls (HC), individuals with lung nodules (LN) and individuals with lung cancer (LC), which are not independent but differed by their radiological features. 1. HC sub-cohort: (1) Permanent community residents or individuals undergoing health examinations who are aged 18 years old and above; (2) Wiling to have low-dose CT scanned; (3) Fully understand and consent to the study, sign the informed consent. 2. LN sub-cohort: (1) Patients from inpatient, outpatient departments and the HC sub-cohort; (2) Pulmonary nodules found with their diameters >= 4mm on CT or LDCT scans; (3) Fully consent would be included in the LN sub-cohort. 3. LC sub-cohort: (2) Those who are confirmed pathologically as lung cancer.

Exclusion criteria

Exclusion criteria: 1.Individuals do not consent to the follow-up and collection of their clinical records including radiological data, pathological data, blood test results, et al.; 2.Individuals have disabilities in understanding or signing the consent.

Design outcomes

Primary

MeasureTime frame
Lung cancer incidence;Lung cancer mortality;

Countries

China

Contacts

Public ContactLi Weimin

West China Hospital, Sichuan University

weimin003@163.com+86 28 85423998

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026